Work

Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect in vivo

Year: 2021

Type: article

Abstract: Our study demonstrated the therapeutic potential of hEND-CD3/BiTE and provided a novel approach to clinical cancer treatment.

Source: Theranostics

DOI: 10.7150/thno.53121

Authors: Liping Zhong, Wei Shi, Lu Gan, Xiuli Liu, Yu Huo, Pan Wu, Zhikun Zhang, Tao Wu, Hongmei Peng, Yong Huang, Yongxiang Zhao, Yulin Yuan, Zhiming Deng, Hongliang Tang

Institutions: Guangxi Medical University, The First People's Hospital of Changde, The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine, Guangxi University of Chinese Medicine, The People's Hospital of Guangxi Zhuang Autonomous Region

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,671

Funder: Natural Science Foundation of Guangxi Province

Awards: G3296009272, G4852697843, G8386318103

OpenAlex ID: W3158280751

FWCI: 0.366

Cites: 60

Cited by: 8

Related to: 10